Search Results
Nov 06, 2025, 19:10 ET ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
Inflammatory Responses: CS2015 lead molecule inhibited the release of inflammatory cytokines from primary CD4+ T cells stimulated by TSLP/OX40L and suppressed TSLP-induced release of TARC (CCL17) in human monocytes and peripheral blood mononuclear cells (PBMC).
More news about: CStone Pharmaceuticals
Nov 06, 2025, 18:52 ET Lunai Bioworks 在臨床前人源化模型內，實現原發性和轉移性胰臟腫瘤的完全消退，標誌為同種異體癌症免疫療法的突破
這項新發表建基於 Lunai 的較早研究（Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749），該研究首次在人源化胰腺癌小鼠體內證明，經過基因改造過度表達 CD40L、CD93 和 CXCL13 的 CD34+ 造血幹細胞 (HSC) 衍生的樹突狀細胞 (DC) 具備強大抗腫瘤活性。雖然最初研究採用研究級慢病毒載體，但最新報告描述一種最佳化兼符合臨床規範的構建體。該構建體保持同等療效，同時改進設計與製造特性，從而支持未來臨床轉化。 第二代構建體具備強大哺乳動物啟動子與已增強遺傳因子，從而驅動重要免疫調節份子的表達。Lunai
More news about: Lunai Bioworks Inc.
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.1 It is the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma. DARZALEX FASPRO® is co-formulated with recombinant human hyaluronidase
More news about: Johnson & Johnson
Nov 06, 2025, 09:30 ET Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
LaunchSuite: A complete, ready-to-deploy solution for generic CAR-T manufacturing. Provides fully characterized CGMP vectors for anti-CD19 and anti-BCMA targets, documentation, and decentralized cell manufacturing process workflows. Designed to simplify CAR-T deployment at
More news about: Vector BioMed
Nov 06, 2025, 08:27 ET Bitrise großer Gewinner bei den DevOps Awards 2025
auf Geschwindigkeit, Zuverlässigkeit und Entwicklerproduktivität. Für Unternehmen mit mobilen Apps bietet Bitrise eine speziell entwickelte CI/CD-Infrastruktur, die auf die besonderen Herausforderungen der mobilen Entwicklung zugeschnitten ist – von komplexen Signierungs- und Bereitstellungsprozessen
More news about: Bitrise
Nov 06, 2025, 08:23 ET Bitrise remporte une grande victoire aux DevOps Awards 2025
vitesse, la fiabilité et la productivité des développeurs. Pour les entreprises ayant des applications mobiles, Bitrise fournit une infrastructure CI/CD spécialement conçue autour des défis uniques du développement mobile - de la signature et du provisionnement complexes à la fragmentation des appareils
More news about: Bitrise
Nov 06, 2025, 07:55 ET Gran triunfo de Bitrise en los DevOps Awards 2025
generar un impacto tangible en velocidad, fiabilidad y productividad. Para las empresas con aplicaciones móviles, Bitrise ofrece una infraestructura de CI/CD diseñada específicamente para abordar los desafíos únicos del desarrollo móvil, desde la firma y el aprovisionamiento complejos hasta la fragmentación
More news about: Bitrise
Nov 06, 2025, 02:00 ET Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), which first demonstrated potent anti-tumor activity of CD34+ hematopoietic stem cell (HSC)-derived DCs engineered to overexpress CD40L, CD93, and CXCL13 in humanized mouse models of pancreatic cancer. While the initial study utilized a research-grade
More news about: Lunai Bioworks Inc.
Nov 05, 2025, 11:00 ET Truth-seeking AI creates world's largest encyclopaedic knowledge portal - 6,000 times larger than Wikipedia
Encyclopaedias have come a long way, from the printed editions of the 1800s and CD ROMs in the 1990s, to today's online crowd-edited Wikipedia. So, what's next? Powered by proprietary AI, Botipedia leverages hundreds
More news about: INSEAD
Nov 05, 2025, 10:57 ET Late-Breaking Clinical Trial Results Announced at VIVA 2025
5 and 50 were RC 3. Twelve-month endpoints included Kaplan-Meier (KM) estimates of freedom from clinically driven target lesion revascularization (CD-TLR) and major target limb amputation. Primary patency, change in RC, and Vascular Quality of Life Questionnaire-6 (VascuQoL-6) scores were also assessed.
More news about: The VIVA Foundation
Nov 05, 2025, 10:00 ET Aptori's Code-Q Closes the Loop on Application Security, From Detection to Remediation
the codebase to reason about intent and generate verifiable, testable fixes. Developers can review, validate and merge directly within their IDE or CI/CD environment. The result is a closed-loop system where every confirmed finding can be remediated quickly and transparently. "Driving
More news about: Aptori
Nov 05, 2025, 09:22 ET Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), which first demonstrated potent anti-tumor activity of CD34+ hematopoietic stem cell (HSC)-derived DCs engineered to overexpress CD40L, CD93, and CXCL13 in humanized mouse models of pancreatic cancer. While the initial study utilized a research-grade
More news about: Lunai Bioworks Inc.
Nov 05, 2025, 08:56 ET CD Valet's October CD Rate Analysis Reveals that Despite Recent Federal Reserve Action, Many CD Rates Remain Competitive
CD Valet's monthly Ratewatcher report analyzes its digital marketplace which includes all CDs offered by financial institutions that publish their CD rates online. This analysis is based on CD Valet's comprehensive data which includes more than 38,500 retail CD rates, representing
More news about: CD Valet
Nov 05, 2025, 08:30 ET Parker Institute for Cancer Immunotherapy Demonstrates Leadership and Showcases Latest Advances in Immunotherapy at SITC 2025 Annual Meeting
Engineered T cell therapy combined with PD-1, Lag-3 and Tim-3 checkpoint inhibition promotes pro-inflammatory CD4 T cell differentiation in an ovarian cancer mouse model (
More news about: Parker Institute for Cancer Immunotherapy
Nov 05, 2025, 08:00 ET Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings
Orlando, Florida Verismo's team will deliver a poster presentation highlighting the potent antitumor activity of SynKIR™-310, a novel CD19-targeted KIR-CAR T cell therapy, in a preclinical mouse model. Location:
More news about: Verismo Therapeutics
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
purpose-built to break through the resistance barriers that limit current PD-1 or CD47 monotherapies," remarked Wenwu Zhai, Ph.D., Chief Scientific Officer of HanchorBio. "Each of its three arms addresses a key axis of tumor immune evasion: CD47 for innate immune clearance, PD-1 for adaptive immune reactivation,
More news about: HanchorBio Inc.
Nov 05, 2025, 07:00 ET Truth-seeking AI creates world's largest encyclopaedic knowledge portal - 6,000 times larger than Wikipedia
Encyclopaedias have come a long way, from the printed editions of the 1800s and CD ROMs in the 1990s, to today's online crowd-edited Wikipedia. So, what's next? Powered by proprietary AI, Botipedia leverages hundreds
More news about: INSEAD
Nov 05, 2025, 04:00 ET Bitrise Wins Big at DevOps Awards 2025
delivering measurable impact across speed, reliability, and developer productivity. For businesses with mobile apps, Bitrise provides purpose-built CI/CD infrastructure designed around the unique challenges of mobile development — from complex signing and provisioning to device fragmentation and frequent
More news about: Bitrise
Nov 05, 2025, 04:00 ET Bitrise Wins Big at DevOps Awards 2025
delivering measurable impact across speed, reliability, and developer productivity. For businesses with mobile apps, Bitrise provides purpose-built CI/CD infrastructure designed around the unique challenges of mobile development — from complex signing and provisioning to device fragmentation and frequent
More news about: Bitrise
Nov 04, 2025, 16:05 ET MATSON, INC. ANNOUNCES THIRD QUARTER 2025 RESULTS
https://register-conf.media-server.com/register/BI5943b35b1672471286990cd51612a1b2 Registered participants
More news about: Matson, Inc.
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Dazodalibep Dazodalibep is a fusion protein that inhibits CD40L. Two Phase 3 studies of dazodalibep in Sjögren's disease are underway. The first study is ongoing in patients with moderate-to-severe
More news about: Amgen
Nov 04, 2025, 09:03 ET HSN Celebrates Country Music and Holiday Cheer from Nashville
showcases by her talented team of brand ambassadors, including an exclusive version of her, A Holly Dolly Christmas 5th Anniversary Collector's Edition CD, Dolly Parton x Kendra Scott jewelry collection, special bundles from her signature Scent from Above and Smoky Mountain fragrance lines, and limited-edition
More news about: HSN
Nov 04, 2025, 09:01 ET AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB → MAPKi): PD-1+ CD8 T-cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved
More news about: Bio-Techne Corporation
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
lymphoid organs after IV injection. ILKN421H selectively expanded stem-like CD8 T and NK cells up to 5-folds and 25-folds respectively in patients with advanced solid tumors.
More news about: iLeukon Therapeutics
Nov 04, 2025, 08:15 ET Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801
Saturday, December 6, 9:30–9:45 AM (local time) at the OCCC – Sunburst Room (W340). GT801 is an innovative anti-CD19 in vivo CAR-T candidate developed using T-cell-targeted lipid nanoparticles (T-LNPs) encapsulating optimized mRNA. Grit Bio leveraged the proprietary
More news about: Grit Biotherapeutics Co., Ltd.